William H. Eaglstein

William H. Eaglstein's AcademicInfluence.com Rankings

Philosophy

#7966

World Rank

#11257

Historical Rank

Ontology

#90

World Rank

#101

Historical Rank

Logic

#4998

World Rank

#6349

Historical Rank

philosophy Degrees

William H. Eaglstein

Biology

#10744

World Rank

#14098

Historical Rank

Biochemistry

#1724

World Rank

#1859

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

William H. Eaglstein's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biochemistry University of California, San Francisco

Why Is William H. Eaglstein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William H. Eaglstein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

THE PIG AS A MODEL FOR HUMAN WOUND HEALING (2001) (911)
Chronic venous insufficiency and venous leg ulceration. (2001) (495)
The effect of occlusive dressings on collagen synthesis and re-epithelialization in superficial wounds. (1983) (389)
Microscopic and physiologic evidence for biofilm‐associated wound colonization in vivo (2008) (368)
The "trap" hypothesis of venous ulceration (1993) (310)
Inhibition of cell proliferation by chronic wound fluid (1993) (272)
Tissue-Engineered Skin (2001) (261)
Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. (1991) (260)
The wound healing process. (1993) (255)
Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. (1992) (228)
Tissue engineering and the development of Apligraf, a human skin equivalent. (1997) (201)
Tissue-engineered skin. Current status in wound healing. (2001) (184)
The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. (1970) (182)
The healing of superficial skin wounds is stimulated by external electrical current. (1983) (181)
New methods for assessing epidermal wound healing: the effects of triamcinolone acetonide and polyethelene film occlusion. (1978) (166)
A Composite Skin Substitute (Graftskin) for Surgical Wounds: A Clinical Experience (1995) (156)
Faster healing and less pain in skin biopsy sites treated with an occlusive dressing. (1991) (152)
Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. (2000) (148)
Detection of basement membrane zone antigens during epidermal wound healing in pigs. (1981) (145)
Wound healing and aging. (1989) (143)
Occlusive wound dressings to prevent bacterial invasion and wound infection. (1985) (142)
Causes and effects of the chronic inflammation in venous leg ulcers. (2000) (132)
Experiences with biosynthetic dressings. (1985) (131)
The clinical spectrum of lipodermatosclerosis. (1993) (130)
Acute excisional wounds treated with a tissue-engineered skin (Apligraf). (1999) (129)
Collagenase in wound healing: effect of wound age and type. (1992) (122)
Optimal use of an occlusive dressing to enhance healing. Effect of delayed application and early removal on wound healing. (1988) (121)
Venous ulcers: pathophysiology and treatment options. (2005) (117)
The effect of a semiocclusive dressing on the microbial population in superficial wounds. (1984) (112)
Electrical stimulation and wound healing. (1990) (112)
Dermal pericapillary fibrin in venous disease and venous ulceration. (1987) (108)
Intradermal Anti-Prostaglandin Agents and Sunburn (1974) (104)
Wound healing. The effects of topical antimicrobial agents. (1979) (101)
Interleukin-1 enhances epidermal wound healing. (1990) (101)
Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites. (1999) (98)
Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. (1970) (95)
Evaluation of Apligraf® persistence and basement membrane restoration in donor site wounds: a pilot study (2006) (90)
Initial rate of healing predicts complete healing of venous ulcers. (1997) (90)
Management of pemphigus with gold compounds: a long-term follow-up report. (1976) (87)
The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. (1999) (82)
A gene signature of nonhealing venous ulcers: potential diagnostic markers. (2008) (81)
Human essential fatty acid deficiency: treatment by topical application of linoleic acid. (1977) (77)
Cyanoacrylates for skin closure. (2005) (75)
Prostaglandin and DNA synthesis in human skin: possible relationship to ultraviolet light effects. (1975) (71)
The biology of skin grafts. Skin grafts as pharmacologic agents. (1993) (68)
Gold sodium thiomalate treatment of pemphigus. (1973) (67)
"Inert" vehicles do affect wound healing. (1980) (66)
The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. (1998) (66)
High-dose methylprednisolone in the treatment of bullous pemphigoid. (1984) (65)
Barrier and Antibacterial Properties of 2-Octyl Cyanoacrylate-Derived Wound Treatment Films (2003) (65)
Wound Healing: The Effects of Topical Antimicrobial Agents (1979) (64)
Topical oxygen emulsion: a novel wound therapy. (2007) (64)
Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. (1989) (62)
Pericapillary fibrin cuffs in venous ulceration. Persistence with treatment and during ulcer healing. (1992) (59)
The development of bioengineered skin. (1998) (58)
Tissue engineering and the development of Apligraf a human skin equivalent. (1998) (57)
Brachioradial pruritus: treatment with topical capsaicin. (1993) (57)
A new in vivo model for the evaluation of topical antiseptics on superficial wounds. The effect of 70% alcohol and povidone-iodine solution. (1984) (56)
A Liquid Adhesive Bandage for the Treatment of Minor Cuts and Abrasions (2002) (56)
Treatment of Herpes Zoster with Sympathetic Blocks (1985) (56)
Effect of occlusive dressings on wound healing. (1984) (55)
Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia (1991) (55)
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. (1998) (55)
The effect of an antimicrobial gauze dressing impregnated with 0.2-percent polyhexamethylene biguanide as a barrier to prevent Pseudomonas aeruginosa wound invasion (2002) (54)
Basal cell carcinoma arising in venous ulcers and mimicking granulation tissue. (1993) (53)
Topical antibiotic treatment of impetigo with mupirocin. (1986) (51)
Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. (2001) (51)
Clinical parameters and transcutaneous oxygen measurements for the prognosis of venous ulcers. (1989) (50)
Topical indomethacin and sunburn. (1974) (47)
Synergistic Effect of Formulated Plasmid and Needle-Free Injection for Genetic Vaccines (1999) (46)
Poor prognosis of arthritis-associated pyoderma gangrenosum. (2004) (45)
Noninflammatory destruction of actinic keratoses by fluorouracil. (1976) (44)
A therapeutic approach to venous ulcers. (1986) (44)
Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. (1993) (43)
Tissue engineering for skin: an update. (1998) (39)
Exogenous electric current can reduce the formation of hypertrophic scars. (1989) (39)
Ultraviolet radiation-induced inflammation and leukocytes. (1979) (38)
Occlusive dressings. (1987) (38)
Collagen fiber orientation as quantified by small angle light scattering in wounds treated with transforming growth factor‐β2 and its neutalizing antibody (1999) (38)
Topical erythromycin and zinc therapy for acne. (1990) (37)
Second-degree burn healing: the effect of occlusive dressings and a cream. (1990) (36)
Early debridement of second-degree burn wounds enhances the rate of epithelization--an animal model to evaluate burn wound therapies. (1996) (36)
Ultraviolet light and tar in the Goeckerman treatment of psoriasis. (1976) (36)
A clinical screening program for topical chemotherapeutic drugs in psoriasis. (1981) (35)
Effect of basement membrane entactin on epidermal cell attachment and growth. (1987) (34)
Occlusive dressings. Does dressing type influence the growth of common bacterial pathogens? (1990) (34)
Identification and content validation of wound therapy clinical endpoints relevant to clinical practice and patient values for FDA approval. Part 1. Survey of the wound care community (2017) (34)
The effect of electrical stimulation on the number of mast cells in healing wounds. (1991) (33)
Protein C and protein S plasma levels in patients with lipodermatosclerosis and venous ulceration. (1990) (33)
Food and Drug Administration (FDA) drug approval end points for chronic cutaneous ulcer studies (2012) (33)
Management of venous ulcers. (1986) (33)
Benzoyl peroxide and epidermal wound healing. (1983) (30)
Wound healing and aging. (1986) (30)
Over-the-counter topical antimicrobials: effective treatments? (2005) (29)
Split‐Thickness Skin Grafting for Lower Extremity Ulcerations (1997) (29)
Dichotomy in response to indomethacin in UV-C and UV-B induced ultraviolet light inflammation. (1975) (29)
Performance comparison of nylon and an absorbable suture material (Polyglactin 910) in the closure of punch biopsy sites. (2000) (29)
Ulcerated edematous limbs: effect of edema removal on transcutaneous oxygen measurements. (1989) (28)
The FDA and designing clinical trials for chronic cutaneous ulcers. (2012) (26)
Terminal illness. (1985) (25)
The Effects of Topical Transforming Growth Factor-β2 and Anti-Transforming Growth Factor-β2,3 on Scarring in Pigs (2000) (25)
Treatment of granuloma annulare with potassium iodide. (1984) (24)
Comparison of suberythemogenic and maximally aggressive ultraviolet B therapy for psoriasis. (1984) (23)
Oxygen diffusion in chronic venous ulceration. (1987) (23)
Effect of topically applied steroidal and nonsteroidal anti-inflammatory agents on skin repair and regeneration. (1984) (22)
The Effect of the Proline Analogue L‐Azetidine-2‐Carboxylic Acid (LACA) on Epidermal and Dermal Wound Repair (1982) (21)
Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf). (2001) (21)
Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. (1996) (20)
Heterogeneity in oxygen diffusion around venous ulcers. (1991) (20)
Petrolatum: interference with the oxidation of arachidonic acid (1980) (20)
Chronic wounds (2022) (20)
Healing of Refractory Sinus Tracts by Dermal Matrix Injection With Cymetra (2003) (20)
Effect of topically applied agents on healing wounds. (1984) (19)
Recombinant Human Platelet‐Derived Growth Factor for Refractory Nondiabetic Ulcers: A Retrospective Series (2002) (19)
Bioengineered skin (1997) (19)
Role of Long-Wave Ultraviolet (1973) (18)
Wound dressings: current and future. (1991) (17)
Clinical and Economic Outcomes with Graftskin for Hard‐to‐Heal Venous Leg Ulcers: A Single‐Center Experience (2002) (17)
Mupirocin treatment of exudative venous ulcers. (1993) (16)
What Are Cosmetics and Cosmeceuticals (2014) (15)
The effects of topical transforming growth factor-beta2 and anti-transforming growth factor-beta2,3 on scarring in pigs. (2000) (14)
Bioengineered skin [2] (1997) (14)
FDA Advisory Committees (2014) (14)
Allergic contact dermatitis to benzoyl peroxide. Report of cases. (1968) (14)
Recruitment of mononuclear cells by endothelial cell binding into wounded skin is a selective, time-dependent process with defined molecular interactions. (1990) (14)
Office techniques for diagnosing skin disease (1978) (12)
Evidence-based medicine, the research-practice gap, and biases in medical and surgical decision making in dermatology. (2010) (12)
Recruitment of mononuclear cells into wounded skin: mechanism and modulation. (1991) (12)
Current wound management: a symposium. (1984) (12)
The use of new antimicrobial gauze dressings: Effects on the rate of epithelialization of partial-thickness wounds (2002) (12)
IL-1 as a potent inducer of wound re-epithelization. (1991) (12)
Expectations for comparative effectiveness and efficacy research: with welcomed questions may come unwelcome answers. (2013) (12)
The wound environment: Implications from research studies for healing and infection (1996) (11)
Irritation by hydrophilic ointment under occlusion. (1973) (11)
New drugs and new molecular entities in dermatology. (2011) (11)
The effects of occlusive dressings on the recruitment of mononuclear cells by endothelial binding into acute wounds. (1992) (11)
Barrier and Antibacterial Properties of 2-Octyl Cyanoacrylate-Derived Wound Treatment Films (2003) (11)
End points in dermatologic clinical trials: A review for clinicians. (2016) (11)
Role of long-wave ultraviolet light in Goeckerman treatment. (1973) (10)
Cymetra: A treatment option for refractory ulcers (2004) (10)
The effect of topical nitroglycerin on transcutaneous oxygen (1991) (9)
Topical Corticosteroid Therapy: Efficacy of Frequent Application (1974) (9)
Occlusive dressings. (1993) (9)
Dermagraft Treatment of Diabetic Ulcers (1998) (9)
Topical hydrocortisone from prescription to over-the-counter sale: a past controversy: a cautionary tale. (2007) (9)
Cryotherapy for psoriasis. (1997) (8)
Studies on the repopulation of Langerhans cells in partial-thickness wounds. Air exposed and occlusively dressed. (1993) (8)
Support and stimulation of epidermal cell outgrowth from porcine skin explants by platelet factors (1986) (8)
Zoster, a recrudescence of VZ virus infection. (1970) (7)
Wound healing. (1988) (7)
Analysis of fibroblast defects in extracellular matrix production in chronic wounds1 (2004) (6)
Inadvertent intracutaneous injection with hypertonic saline (23.45%) in two patients without complication. (1990) (6)
A porcine model for evaulating epidermal wound healing (1986) (6)
The role of mandated research during dermatology residency training. (1999) (6)
Dermatologic comorbidities of diabetes mellitus and related issues. (2009) (6)
Effect of platelet homogenate on in vitro glycosaminoglycans production by dermal fibroblasts from systemic sclerosis patients and normal controls (1985) (6)
Systemic antibiotic therapy of secondary infected dermatitis. (1977) (5)
Editorial: Topical corticosteroid therapy: efficacy of frequent application. (1974) (5)
Techniques for Diagnosing Skin and Hair Disease (1986) (5)
An analysis of advertisements in the Journal of the American Academy of Dermatology, 1980 and 1990. (1993) (5)
An all-day test for the evaluation of a topical sunscreen. (1980) (5)
Challenges encountered in dermatologic drug development. (2009) (4)
INDOMETHACIN: TREATMENT FOR SUNBURN OR INVESTIGATIVE TOOL IN ULTRAVIOLET INFLAMMATION? (1975) (4)
Me-too drugs and me-too people. (2013) (4)
Victor H. Witten, MD: creator of the National Library of Medicine "Audio History of Dermatology". (2008) (4)
Methods to speed healing after skin biopsy or trichloroacetic acid chemical peel. (1991) (3)
Analysis of fibroblast defects in extracellular matrix production in chronic wounds 1 1 Disclosure not available at press time. (2004) (3)
The FDA Drug Approval Process (2021) (3)
Real-world evidence-What is it and does it matter for approval of drugs? (2018) (3)
Leg and Foot Ulcers: A Clinician's Guide (1995) (3)
Biosynthetic Dressing Materials and their Influence on Wound Healing and Infection (1990) (3)
UV-B-energy distribution in phototherapy equipment. (1984) (3)
From Occlusive to Living Membranes (1998) (2)
Why train residents and teach students in dermatology. (1995) (2)
Dermatology in the U.S.A. (1998) (2)
Chronic Leg Ulcers in a Patient with Combined Arterial and Venous Disease Successfully Treated with a Human Skin Equivalent: A Case Report (2000) (2)
Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy. (2016) (2)
Fibronectin receptor function. (1986) (2)
Cryotherapy for Psoriasis (1998) (2)
Patient referrals to a dermatologist. The referring physician's perspective. (1996) (2)
The FDA for Doctors (2014) (1)
Problems in pigmentation. (1976) (1)
What Are Drugs (2014) (1)
Topical Antiseptics-Reply (1984) (1)
The body politic (1981) (1)
Clinical trials in perspective. (2011) (1)
Dermal and transdermal absorption, Dr. Rainer Brandau, Dr. Bärbel H. Lippold (Eds.). Heyden & Son Inc., Philadelphia (1982), 257, $49 (1985) (1)
Challenges Encountered in Dermatologic Drug Development (2009) (1)
Harvey Blank, 1918-2001 (2003) (0)
The FDA: Doctors, Investigators, and Translational Research. (2015) (0)
Recurrent cellulitis [6] (1994) (0)
The New Drug Application (NDA), the Investigative New Drug Exemption (IND) and the General Drug Approval Pathway (2014) (0)
Issue Information (2017) (0)
Doctors and the FDA (2014) (0)
Volume 135, Issue 11-November 2015. (2015) (0)
Enforcement and Warning Letters (2014) (0)
FDA Exclusivity and Patents (2014) (0)
What Are Biologics, Biological Products and Biological Drugs? (2014) (0)
Report of the workshop on training clinical researchers in arthritis and musculoskeletal and skin diseases. (1997) (0)
Practice management for academic dermatology departments. (2000) (0)
Testing of Skin Cap (1999) (0)
Cutaneous gumma--a contemporary disease. (1969) (0)
What Is the FDA and What Does It Do (2014) (0)
Zoster , a recrudescence of VZ virus infection HARVEY BLANK (2008) (0)
The FDA, Politics and Criticism (2014) (0)
Harvey Blank, 1918–2001 (2003) (0)
Socioeconomics--two myths too much. (1986) (0)
Off-Label Use (2014) (0)
Effects of occlusive dressings on the repopulation of langerhans cells in partial thickness wounds (1991) (0)
Protein C and Fibrinolysis-Reply (1991) (0)
FDA, Labels and Labeling for Medical Products (2014) (0)
Gold Compounds vs Corticosteroids in the Treatment of Pemphigus Vulgaris-Reply (1976) (0)
FDA Rule Making and Guidances (2014) (0)
Tissue engineering and the development of Apligraf, a human skin equivalent. (1997) (0)
What Are Devices (2014) (0)
What Are Dietary Supplements and Nutraceuticals (2014) (0)
Ronald Marks (2020) (0)
Reviews and Notes: Dermatology: Leg and Foot Ulcers: A Clinician's Guide (1995) (0)
Inadequacies in a Wound Infection Study-Reply (1984) (0)
What Are Combination Products (2014) (0)
017 Laminin 10 in Wound Reepithelization and Angiogenesis (2008) (0)
The authors reply (2002) (0)
FDA and Product Names (2014) (0)
090 Extracellular Matrix Regulation and Dermal Repair in Burn Wound (2008) (0)
Treatment of psoriasis with cryotherapy (1998) (0)
Foods, Doctors and the FDA (2014) (0)
Brief History of the FDA (2014) (0)
FDA and Tobacco Products (2014) (0)
Adverse Event Reporting, Pharmacovigilance and FDA (2014) (0)
Additional Drug Approval Pathways and Expanded Access (Treatment INDs); and Personal Importation of Unapproved Drugs (2014) (0)
E-Z DERM??? A Porcine Heterograft Material (2002) (0)
Harvey Blank's impact on dermatology. (1989) (0)
055 The Effect of an Oxygen Emulsion on Collagen Deposition in Second‐Degree Burn Wound Repair (2004) (0)
Topical erythromycin and zinc for acne (Reply) (1991) (0)
FDA and Promotion and Advertising (2014) (0)
Dohi Memorial Lecture. From occlusive to living membranes. (1998) (0)
The FDA Approval Process and Drug Development (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William H. Eaglstein?

William H. Eaglstein is affiliated with the following schools:

University of Miami

William H. Eaglstein's Academic­Influence.com Rankings

William H. Eaglstein's Degrees

Why Is William H. Eaglstein Influential?

William H. Eaglstein's Published Works

Published Works

What Schools Are Affiliated With William H. Eaglstein?

William H. Eaglstein's AcademicInfluence.com Rankings